Having trouble accessing articles? Reset your cache.

Two Ebola therapies best ZMapp in Congo trial

All patients in an Ebola trial in the Democratic Republic of the Congo will be offered treatments from Regeneron and NIAID after they were shown to be superior to ZMapp in preventing death in the PALM platform study.

Trial co-sponsors NIH

Read the full 407 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE